Our study aims to validate clinicopathological predictors of chemotherapy responsiveness (including histological grade and a Ki67 index ≥20%), with the ultimate goal of developing a cost-effective predictive model specifically designed for Chinese patients.<h4>Methods</h4>This retrospective study included surgically treated intermediate-risk breast cancer patients from Huizhou Third Municipal Hospital (2015-2022). The gene discussed is MKI67; the disease is breast cancer.